Document
MYRBETRIQ GRANULES, 213801, Review Administrative and Correspondence Documents (Orange Book Mar. 25, 2021)
Cite Document
MYRBETRIQ GRANULES, 213801, Review Administrative and Correspondence Documents (Orange Book Mar. 25, 2021)
+ More Snippets
Document
MYRBETRIQ GRANULES, 213801, Review Other Reviews (Orange Book Mar. 25, 2021)
Cite Document
MYRBETRIQ GRANULES, 213801, Review Other Reviews (Orange Book Mar. 25, 2021)
+ More Snippets
Document
MYRBETRIQ GRANULES, 213801, Letter (Orange Book Mar. 25, 2021)
Cite Document
MYRBETRIQ GRANULES, 213801, Letter (Orange Book Mar. 25, 2021)
+ More Snippets
Document
MYRBETRIQ GRANULES, 213801, Label (Orange Book Mar. 25, 2021)
Cite Document
MYRBETRIQ GRANULES, 213801, Label (Orange Book Mar. 25, 2021)
+ More Snippets
Document
IPR2018-00079, No. 2004-31 Exhibit - Myrbetriq What is Myrbetriq (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2004-31 Exhibit - Myrbetriq What is Myrbetriq (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2001-28 Exhibit - Myrbetriq mirabegron Product Label, extended release tablets, revised July 2017 (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2001-28 Exhibit - Myrbetriq mirabegron Product Label, extended release tablets, revised July 2017 (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2003-30 Exhibit - Myrbetriq Mechanism of Action (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2003-30 Exhibit - Myrbetriq Mechanism of Action (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2005-32 Exhibit - WO9716189 (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2005-32 Exhibit - WO9716189 (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2006-33 Exhibit - File History of US Patent Application 08233,166 (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2006-33 Exhibit - File History of US Patent Application 08233,166 (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2002-29 Exhibit - Orange Book Approved Drug Products with Therapeutic Equivalent Evaluations, FDA (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2002-29 Exhibit - Orange Book Approved Drug Products with Therapeutic Equivalent Evaluations, FDA (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2005 Exhibit - WO9716189 (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2005 Exhibit - WO9716189 (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2003 Exhibit - Myrbetriq Mechanism of Action (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2003 Exhibit - Myrbetriq Mechanism of Action (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2002 Exhibit - Orange Book Approved Drug Products with Therapeutic Equivalent Evaluations, FDA (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2002 Exhibit - Orange Book Approved Drug Products with Therapeutic Equivalent Evaluations, FDA (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2004 Exhibit - Myrbetriq What is Myrbetriq (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2004 Exhibit - Myrbetriq What is Myrbetriq (P.T.A.B. Feb. 8, 2018)
+ More Snippets
Document
IPR2018-00079, No. 2001 Exhibit - Myrbetriq mirabegron Product Label, extended release tablets, revised July 2017 (P.T.A.B. Feb. 8, 2018)
Cite Document
IPR2018-00079, No. 2001 Exhibit - Myrbetriq mirabegron Product Label, extended release tablets, revised July 2017 (P.T.A.B. Feb. 8, 2018)
+ More Snippets